We launched Pairnomix in 2016 with the goal of helping patients and physicians better understand a rare genetic mutation.
One of the most exciting developments in the study of rare diseases is genetic sequencing. As important as it is to identify the genetic mutation responsible for an individual’s mutation, that’s only the beginning. Pairnomix picks up where sequencing leaves off and provides highly personalized evaluations of rare genetic mutations. Our research service involves creating a laboratory model of an individual’s genetic mutation, evaluating the mutation’s functional consequence, and testing more than 1,300 approved drugs against the modeled mutation for their abilities to reverse the mutation’s functional consequence.
While we have begun our work within the rare genetic neurological disease setting, we plan to expand our services and the indications we evaluate. We hope to provide valuable information to physicians as we pursue our mission of empowering individuals who are living with rare genetic conditions.
Matthew Fox, CEO